Researchers say erenumab is ‘incredibly important step forward’ for condition that affects 8.5 million people in UK

A new migraine drug that can halve the length of attacks has been hailed as “the start of real change” in how the condition is treated.

Erenumab, a laboratory-made antibody that blocks a neural brain pathway called CGRP, is the first drug in 20 years proven to prevent migraine attacks.

Continue reading…

Facebook Comments

This site uses Akismet to reduce spam. Learn how your comment data is processed.